{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:02:52Z","timestamp":1759341772564},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"J. Jacobi Trust"},{"name":"OphthalmoPharma Ltd, Sarnen, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microvascular Research"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.mvr.2011.10.004","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T18:54:39Z","timestamp":1319828079000},"page":"105-110","source":"Crossref","is-referenced-by-count":12,"title":["Angiogenesis inhibition by the maleimide-based small molecule GNX-686"],"prefix":"10.1016","volume":"83","author":[{"given":"Patrycja","family":"Nowak-Sliwinska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Storto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Cataudella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Ballini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Gatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Plyte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Wagni\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mvr.2011.10.004_bb0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00004397-200404430-00006","article-title":"Sustained-release drug implants for the treatment of intraocular disease","volume":"44","author":"Acharya","year":"2004","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.mvr.2011.10.004_bb0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.brainresbull.2009.08.001","article-title":"Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole","volume":"81","author":"Afzal","year":"2010","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.mvr.2011.10.004_bb0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.addr.2006.07.022","article-title":"Industrial perspective in ocular drug delivery","volume":"58","author":"Ali","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mvr.2011.10.004_bb0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0039-6257(03)00030-4","article-title":"Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies","volume":"48","author":"Ambati","year":"2003","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0025","first-page":"2314","article-title":"Photodynamic therapy with verteporfin for age-related macular degeneration","volume":"107","author":"American Academy of Ophthalmology","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2011.10.004_bb0030","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ophtha.2007.02.021","article-title":"Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration","volume":"114","author":"Apte","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2011.10.004_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/138945011794182746","article-title":"Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration","volume":"12","author":"Becerra","year":"2011","journal-title":"Curr. Drug Targets"},{"issue":"600\u2013600","key":"10.1016\/j.mvr.2011.10.004_bb0040","first-page":"e2","article-title":"Comparing ranibizumab with bevacizumab","volume":"118","author":"Biswas","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mvr.2011.10.004_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.mvr.2011.10.004_bb0050","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mvr.2011.10.004_bb0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/ICU.0b013e32834597d9","article-title":"Preferred therapies for neovascular age-related macular degeneration","volume":"22","author":"Chiang","year":"2011","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187221108783331410","article-title":"Recent patents on ocular drug delivery systems","volume":"2","author":"Conway","year":"2008","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.mvr.2011.10.004_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajo.2010.04.006","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial","volume":"150","author":"Donahue","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0070","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/02713680802226582","article-title":"Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186","volume":"33","author":"Falkenstein","year":"2008","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.mvr.2011.10.004_bb0075","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/eye.2011.18","article-title":"Comment on \u2018Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial\u2019","volume":"25","author":"Fayers","year":"2011","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.mvr.2011.10.004_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.mvr.2011.10.004_bb0085","first-page":"514","article-title":"Retinopathy of prematurity\u2014epidemics, incidence, prevalence, blindness","volume":"111","author":"Gergely","year":"2010","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.mvr.2011.10.004_bb0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bjo.80.2.101","article-title":"Submacular surgery for choroidal neovascularisation","volume":"80","author":"Kaplan","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0095","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10384-010-0863-4","article-title":"Treatment of age-related macular degeneration: beyond VEGF","volume":"54","author":"Miller","year":"2010","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0100","series-title":"Proc SPIE. 7380a","doi-asserted-by":"crossref","DOI":"10.1117\/12.822967","article-title":"Vascular effects induced by anti-VEGF agents in the CAM model: effect of the DMSO","author":"Nowak-Sliwinska","year":"2009"},{"key":"10.1016\/j.mvr.2011.10.004_bb0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mvr.2009.10.004","article-title":"Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model","volume":"79","author":"Nowak-Sliwinska","year":"2010","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.mvr.2011.10.004_bb0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10456-010-9185-x","article-title":"Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane","volume":"13","author":"Nowak-Sliwinska","year":"2010","journal-title":"Angiogenesis"},{"key":"10.1016\/j.mvr.2011.10.004_bb0115","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1021\/jm2002074","article-title":"Organometallic ruthenium(II)-arene compounds with anti-angiogenic activity","volume":"54","author":"Nowak-Sliwinska","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mvr.2011.10.004_bb0120","doi-asserted-by":"crossref","unstructured":"Nowak-Sliwinska, P., et al., in press. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J. Cell. Mol. Med. doi:10.1111\/j.1582-4934.2011.01440.x. [Epub ahead of print] Sep 1.","DOI":"10.1111\/j.1582-4934.2011.01440.x"},{"key":"10.1016\/j.mvr.2011.10.004_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0360-3016(97)00296-4","article-title":"Radiation therapy for ocular choroidal neovascularization (phase I\/II study): preliminary report","volume":"39","author":"Sasai","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.mvr.2011.10.004_bb0130","first-page":"2337","article-title":"Retinal vascular permeability suppression by topical application of a novel VEGFR2\/Src kinase inhibitor in mice and rabbits","volume":"118","author":"Scheppke","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mvr.2011.10.004_bb0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/ICU.0b013e3283386783","article-title":"Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review","volume":"21","author":"Schmucker","year":"2010","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0140","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1586\/era.09.157","article-title":"Update on novel agents in renal cell carcinoma","volume":"9","author":"Tamaskar","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.mvr.2011.10.004_bb0145","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2174\/156652409789712783","article-title":"Current molecular understanding and future treatment strategies for pathologic ocular neovascularization","volume":"9","author":"Tolentino","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.mvr.2011.10.004_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1076\/soph.16.4.181.10299","article-title":"Photodynamic therapy of age-related macular degeneration: history and principles","volume":"16","author":"van den Bergh","year":"2001","journal-title":"Semin. Ophthalmol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0155","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/JTO.0b013e318180275e","article-title":"Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib","volume":"3","author":"Vasile","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/0471142727.mb2801s70","article-title":"Preparation, culture, and immortalization of mouse embryonic fibroblasts","author":"Xu","year":"2005","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"10.1016\/j.mvr.2011.10.004_bb0165","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.addr.2005.09.005","article-title":"Intraocular sustained drug delivery using implantable polymeric devices","volume":"57","author":"Yasukawa","year":"2005","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Microvascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286211001762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286211001762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T22:22:13Z","timestamp":1543443733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026286211001762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0026286211001762"],"URL":"https:\/\/doi.org\/10.1016\/j.mvr.2011.10.004","relation":{},"ISSN":["0026-2862"],"issn-type":[{"value":"0026-2862","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}